Maravai Lifesciences Holdings (MRVI) EBT Margin (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly EBT Margin of 9.92% for Q1 2026, up 10255.0% year-over-year from N/an in Q1 2025, and up 92.15% quarter-over-quarter from 126.36% in Q4 2025.
Powered by 
Analysis
Maravai Lifesciences Holdings (MRVI) EBT Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' EBT Margin history runs 7 years deep, the most recent figure standing at 9.92% for Q1 2026.
- In Q1 2026, EBT Margin rose 10255.0% year-over-year to 9.92%; the TTM figure through Mar 2026 stood at 92.22% (up 2841.0% YoY), while the FY2025 annual figure was 126.5%, down 2562.0% from the prior year.
- EBT Margin for Q1 2026 stood at 9.92%, up from 126.36% in the prior quarter.
- The five-year high for EBT Margin was 885.05% in Q4 2023, with the low at 249.39% in Q3 2024.
- The 5-year median for EBT Margin is 30.04% (2024), against an average of 9.79%.
- The sharpest annual moves came in 2023 and 2024: EBT Margin surged 83822 bps in 2023, then sank 96651 bps in 2024.
- Maravai Lifesciences Holdings' EBT Margin stood at 46.83% in 2022, then surged by 1790 bps to 885.05% in 2023, then sank by 109 bps to 81.46% in 2024, then plunged by 55 bps to 126.36% in 2025, then soared by 92 bps to 9.92% in 2026.
- Business Quant data shows MRVI's EBT Margin at 9.92% in Q1 2026, 126.36% in Q4 2025, and 108.45% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Maravai Lifesciences Holdings | 1.09 Bn | 1.02 Bn | 20.65 Mn | -42.38% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.38% |
| Mar 31, 2026 | -9.92% |
| Dec 31, 2025 | -126.36% |
| Sep 30, 2025 | -108.45% |
| Jun 30, 2025 | -156.39% |
| Mar 31, 2025 | -112.47% |
| Dec 31, 2024 | -81.46% |
| Sep 30, 2024 | -249.39% |
| Jun 30, 2024 | -30.04% |
| Mar 31, 2024 | -34.92% |
| Dec 31, 2023 | 885.05% |
| Sep 30, 2023 | -30.75% |
| Jun 30, 2023 | -19.39% |
| Mar 31, 2023 | -5.72% |
| Dec 31, 2022 | 46.83% |
| Sep 30, 2022 | 59.48% |
| Jun 30, 2022 | 72.09% |
| Mar 31, 2022 | 68.30% |
| Dec 31, 2021 | 63.34% |
| Sep 30, 2021 | 73.74% |